SOST and osteoporosis: Studies in mice and in vitro are rather consistent, showing increased expression of sclerostin after glucocorticoid therapy and a protective role of anti-sclerostin antibodies against glucocorticoid-induced osteoporosis (19, 20, 22, 40), but in humans, results are so far contradictory.